1/30
09:47 am
plx
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
High
Report
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
1/5
06:50 am
plx
Protalix BioTherapeutics Letter to Stockholders
Low
Report
Protalix BioTherapeutics Letter to Stockholders
12/22
09:22 am
plx
PLX: Secarna's Antisense Oligonucleotide Discovery Collaboration [Yahoo! Finance]
Low
Report
PLX: Secarna's Antisense Oligonucleotide Discovery Collaboration [Yahoo! Finance]
12/17
07:17 am
plx
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement [Yahoo! Finance]
Medium
Report
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement [Yahoo! Finance]
12/17
06:50 am
plx
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
Medium
Report
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
11/21
08:05 am
plx
Protalix BioTherapeutics (NYSE:PLX) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
Protalix BioTherapeutics (NYSE:PLX) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.
11/13
06:50 am
plx
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
High
Report
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results